Tesamorelin vs Sermorelin vs CJC-1295: Comparing the GHRH Analogs
Tesamorelin, sermorelin and CJC-1295 are three of the most frequently compared compounds in growth-hormone-axis peptide research. All three are analogs of growth-hormone-releasing hormone (GHRH), meaning they prompt the pituitary to release the body's own growth hormone rather than supplying it directly. Yet they differ sharply in structure, stability and how long they stay active. This overview compares the three for educational and research context only.
What a GHRH analog actually is
Native GHRH is a 44-amino-acid signalling peptide released by the hypothalamus. It binds the GHRH receptor on pituitary somatotroph cells and triggers a pulse of growth hormone. The biologically active core sits in the first 29 amino acids, which is why several research analogs are built around that fragment.
Because the unmodified fragment is broken down quickly by the enzyme DPP-4, the main difference between these three compounds comes down to how each one resists degradation — and therefore how long it remains active in a research setting.
Sermorelin: the short-acting parent fragment
Sermorelin is a synthetic copy of the first 29 amino acids of GHRH, GHRH(1–29). It is the least modified of the three, which makes it the most susceptible to rapid enzymatic breakdown. The literature reports an effective half-life of roughly 15 minutes, so its signal is brief and closely mimics a natural GH pulse. That short, pulsatile profile is a large part of why it remains a reference compound in GHRH research. Our sermorelin research overview covers it in more detail.
CJC-1295: stabilising the fragment
CJC-1295 keeps the GHRH(1–29) core but introduces four amino-acid substitutions designed to resist enzymatic degradation, the most important being at position 2, where native alanine is replaced with D-alanine to block DPP-4 cleavage. The "No DAC" form has a reported half-life near 30 minutes, while a Drug Affinity Complex (DAC) version can extend activity to several days by binding to serum albumin. In research it is often paired with a ghrelin-mimetic such as ipamorelin; we discuss that combination in CJC-1295 and Ipamorelin: What the Research Says.
Tesamorelin: the full-length, clinically studied analog
Tesamorelin is the only one of the three based on the full 44-amino-acid GHRH sequence. It carries a single modification at the N-terminus — a trans-3-hexenoic acid group attached to the terminal tyrosine — that sterically blocks DPP-4. It is also the most clinically developed: tesamorelin is an FDA-approved compound for a narrow indication (HIV-associated lipodystrophy), giving it a more substantial human-research record than most peptides in this class. See our tesamorelin research overview for the detail.
How researchers choose between them
The practical distinction is pharmacokinetics and evidence tier. Sermorelin offers a brief, natural-style pulse; CJC-1295 extends the signal; tesamorelin combines DPP-4 resistance with the most developed clinical record. All three engage the same GHRH receptor, so the choice in a study design usually comes down to the desired duration of action and the depth of existing literature. For a broader framing, our guide on HGH vs growth hormone secretagogues places these analogs against direct GH and ghrelin-mimetic compounds such as ipamorelin.
Handling and storage
Like most peptides in this category, these analogs are supplied as a lyophilised (freeze-dried) powder, kept cold and protected from light, then reconstituted with bacteriostatic water for laboratory work. If you are new to that process, our step-by-step reconstitution guide and the on-site peptide calculator walk through preparing a solution and calculating concentration. In-stock GHRH-axis options include tesamorelin and the CJC-1295 + ipamorelin blend, each shipped with a per-batch Certificate of Analysis.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.